Second, previous reports showing the predictive value of TOP2A amplified compared anthracycline-based chemotherapy regimens with CMF [11], which is no longer used as a standard treatment regimen for HER2 positive breast cancer. This evidence concerns the gene TOP2A and breast cancer.